Literature DB >> 12463159

Matrix metalloproteinases in cancer.

Yoshifumi Itoh1, Hideaki Nagase.   

Abstract

The extracellular matrix (ECM) holds cells together and maintains the three-dimensional structure of the body. It also plays critical roles in cell growth, differentiation, survival and motility. For a tumour cell to metastasize from the primary tumour to other organs, it must locally degrade ECM components that are the physical barriers for cell migration. The key enzymes responsible for ECM breakdown are matrix metalloproteinases (MMPs). To date, 23 MMP genes have been identified in humans and many are implicated in cancer. ECM degradation by MMPs not only enhances tumour invasion, but also affects tumour cell behaviour and leads to cancer progression. This review highlights recent developments with regard to the cellular and molecular mechanisms of MMPs that influence tumour cell growth, invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12463159     DOI: 10.1042/bse0380021

Source DB:  PubMed          Journal:  Essays Biochem        ISSN: 0071-1365            Impact factor:   8.000


  83 in total

1.  Low expression of RECK indicates a shorter survival for patients with invasive breast cancer.

Authors:  Yue Zhang; Shaoqiang Cheng; Guoqiang Zhang; Wenjie Ma; Yang Liu; Rui Zhao; Qingyuan Zhang; Da Pang
Journal:  Cancer Sci       Date:  2012-04-19       Impact factor: 6.716

Review 2.  Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology.

Authors:  Mahavir Singh; Suresh C Tyagi
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

3.  Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters.

Authors:  Kathryn M Taylor; Helen E Morgan; Andrea Johnson; Lisa J Hadley; Robert I Nicholson
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

4.  Impact of Reck expression and promoter activity in neuronal in vitro differentiation.

Authors:  Marina Trombetta-Lima; Thais Assis-Ribas; Ricardo C Cintra; Joana D Campeiro; Juliano R Guerreiro; Sheila M B Winnischofer; Isis C C Nascimento; Henning Ulrich; Mirian A F Hayashi; Mari C Sogayar
Journal:  Mol Biol Rep       Date:  2021-02-22       Impact factor: 2.316

Review 5.  MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer.

Authors:  Anjum Sohail; Qing Sun; Huiren Zhao; M Margarida Bernardo; Jin-Ah Cho; Rafael Fridman
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

6.  KAI1 is a potential target for anti-metastasis in pancreatic cancer cells.

Authors:  Jian-Hua Xu; Xiao-Zhong Guo; Li-Nan Ren; Li-Chun Shao; Min-Pei Liu
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

7.  A Cycloaddition Strategy for Use toward Berkelic Acid, an MMP Inhibitor and Potent Anticancer Agent Displaying a Unique Chroman Spiroketal Motif.

Authors:  Yaodong Huang; Thomas R R Pettus
Journal:  Synlett       Date:  2008-05-11       Impact factor: 2.454

8.  Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas.

Authors:  Elke Roeb; Marlies Arndt; Bettina Jansen; Volker Schumpelick; Siegfried Matern
Journal:  Int J Colorectal Dis       Date:  2004-04-22       Impact factor: 2.571

9.  MT1-MMP- and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices.

Authors:  Kevin E Fisher; Anastasia Sacharidou; Amber N Stratman; Anne M Mayo; Sarah B Fisher; Rachel D Mahan; Michael J Davis; George E Davis
Journal:  J Cell Sci       Date:  2009-11-24       Impact factor: 5.285

10.  Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.

Authors:  Rita C S Figueira; Luciana R Gomes; João S Neto; Fabricio C Silva; Ismael D C G Silva; Mari C Sogayar
Journal:  BMC Cancer       Date:  2009-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.